Latest Endometriosis Stories
Researchers at Yale School of Medicine have, for the first time, described the genetic basis of endometriosis, a condition affecting millions of women that is marked by chronic pelvic pain and infertility. The researchers' discovery of a new gene mutation provides hope for new screening methods. Published in the Feb. 3 early online issue of EMBO Molecular Medicine, the study explored an inherited mutation located in part of the KRAS gene, which leads to abnormal endometrial growth and...
Hosted by the Endometriosis Foundation of America (New York, NY) -- The Endometriosis Foundation of America (EFA) will hold its Third Annual EFA Scientific/Surgical Symposium on Wednesday, March 14, 2012 (7:30 a.m. – 5:00 p.m.) – Thursday March 15, 2012 (7:30 a.m. – 4:00 p.m.) at Lenox Hill Hospital’s Einhorn Auditorium – 131 E. 76th Street between Park and Lexington Avenues. Tamer Seckin, co-founder and EFA President, is Program Chair of the conference. Scientific Program...
SAN DIEGO, Feb. 2, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2011 financial results after the Nasdaq market closes on Wednesday, February 8, 2012. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, February 8, 2012 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access...
SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual J. P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California. The corporate presentation will review the Company accomplishments in 2011, as well as outline the corporate plans for 2012 and beyond. Specifically,...
Author and activist Karen Steward cautioned today that as the number of opioid pain medication prescriptions for chronic abdominal pain rises, doctors may overlook the signs of intestinal adhesions, a potentially life-threatening condition. (PRWEB) December 29, 2011 Adhesion Related Disorder activist, Karen Steward, today shared concerns voiced by the American Gastroenterological Association (AGA) about a new study that reveals an increase in opioid pain medication prescriptions for...
Texas Fertility Center Reproductive Endocrinologists Drs. Thomas Vaughn & Kaylen Silverberg have been asked to work with the Texas Institute of Robotic Surgery to bring the benefits of da Vinci robotic surgery to fertility patients in Central Texas. Austin, Texas (PRWEB) December 27, 2011 Texas Fertility Center Reproductive Endocrinologists Drs. Kaylen Silverberg and Thomas Vaughn have been asked to work with the Texas Institute of Robotic Surgery at St. David’s North Austin Medical...
Increased risk of inflammatory bowel disease in women with endometriosis: a nationwide Danish cohort study Women with endometriosis are up to twice as likely to develop inflammatory bowel disease as those without this reproductive disorder, suggests a large study published online in Gut. And the effect can last for up to 20 years after their diagnosis of endometriosis—a condition in which cells from the womb lining implant in other areas of the body. Endometriosis is relatively...
A natural “hands-on†treatment to treat infertility, pain and recurring bowel obstruction is now available in Indianapolis, Indiana. Clear Passage Physical Therapy introduced their newest physical therapist-director Amy Robinson, as a certified practitioner in November, 2011. Indianapolis, IN (PRWEB) December 19, 2011 Clear Passage Physical Therapy, which provides a unique hands-on treatment to patients from around the world, opened a new clinic in Indianapolis, Indiana in...
SAN DIEGO, Oct. 31, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2011. For the third quarter of 2011, the Company reported net income of $31.4 million, or $0.56 per fully diluted share outstanding, compared to net income of $3.3 million, or $0.06 per fully diluted share outstanding, for the same period in 2010. For the nine months ended September 30, 2011, the Company reported a net income of $36.2...
SAN DIEGO, Oct. 4, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has achieved its second milestone in its collaboration with Abbott for elagolix and next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. The Company and Abbott held a pre- phase III meeting with the FDA, the outcome of which generated a $20 million milestone payment from Abbott to the Company. This milestone event brings the total milestones achieved by the...
